Kardatuxan (Rivaroxaban)

• Kardatuxan acts on the coagulation cascade to prevent clot formation in several high‑risk conditions.
• Non‑valvular atrial fibrillation: reduces the risk of stroke and systemic embolism.
• Deep vein thrombosis (DVT): treats acute DVT and helps prevent recurrence.
• Pulmonary embolism (PE): treats acute PE and lowers the chance of further embolic events.
• Post‑orthopedic surgery prophylaxis: lowers incidence of DVT after major joint procedures.

• Rivaroxaban selectively inhibits factor Xa, a key enzyme in the conversion of prothrombin to thrombin. By blocking this step, it reduces thrombin generation and subsequent fibrin clot formation, providing anticoagulant activity without the need for antithrombin activation.

Rivaroxaban may cause a range of adverse reactions, most of which are related to bleeding.

Common Side Effects

• Minor bleeding (e.g., nosebleeds, gum bleeding)
• Nausea
• Diarrhea
• Headache
• Dizziness
• Fatigue

Serious or Rare Side Effects

• Major bleeding (intracranial, gastrointestinal)
• Hepatic injury
• Allergic reactions including anaphylaxis
• Spontaneous hematoma
• Thrombocytopenia
• Severe skin reactions (e.g., Stevens‑Johnson syndrome)

Before initiating therapy, consider patient‑specific factors and monitor appropriately.

• Renal impairment: adjust therapy as advised by the prescriber.
• Hepatic disease: use with caution due to altered metabolism.
• Concomitant anticoagulants or antiplatelet agents: increased bleeding risk.
• Surgery or invasive procedures: discontinue according to clinical guidelines.
• Pregnancy and breastfeeding: safety not established; avoid unless essential.
• Store at ambient temperature: keep in the original container, protect from moisture and light.

Rivaroxaban interacts with several drug classes that can modify its anticoagulant effect.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations.
• Antiplatelet agents (e.g., clopidogrel, aspirin): heightened risk of bleeding.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): additive bleeding potential.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors (e.g., erythromycin, clarithromycin): may raise drug levels.
• P‑glycoprotein inhibitors (e.g., amiodarone, verapamil): can increase exposure.
• Herbal supplements such as St. John’s wort: may reduce efficacy by inducing metabolism.